All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Recipient: Wren Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 30, 2020
Details:
The collaboration will use Wren’s network kinetics drug discovery platform, alongside Eisai’s extensive experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Humira
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2020
Details:
Approval is based on the data from a Japanese phase III clinical trial. The proportion of patients achieving at 100 of the target pyoderma gangrenosum ulcer area reduction at Week 26 of Humira administration was 54.5% in the trail.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lenvatinib
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
New safety and efficacy data on LENVIMA® (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, will be presented from two trials in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
CLEAR is a multi-center, randomized, open-label, Phase 3 trial evaluating LENVIMA in combination with KEYTRUDA or in combination with everolimus versus sunitinib alone for the first-line treatment of patients with advanced RCC.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Denileukin Diftitox,Anti-PD-1 agent
Therapeutic Area: Oncology Product Name: E7777
Highest Development Status: Preclinical Product Type: Large molecule
Recipient: Dr. Reddy's Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Combination of E7777 with an anti-PD-1 agent provided clear benefit both in terms of tumor growth control, and a highly significant improvement in overall survival.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: BioArctic AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
For the patients who received BAN2401 10 mg/kg either monthly or every other week in the core study, the amyloid levels in the brain were already low when they entered the open-label extension study and remained low.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aducanumab
Therapeutic Area: Neurology Product Name: BIIB037
Highest Development Status: Phase III Product Type: Large molecule
Recipient: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Details:
Data from Study 103 (PRIME) provide supportive evidence of the effectiveness of aducanumab's eventual approval, boosting chances that Biogen's drug could the market for Alzheimer's patients in the future.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lenvatinib,Everolimus
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Data includes an oral presentation on results from a Phase 2 trial evaluating starting doses of LENVIMA in combination with everolimus (LEN+EVE).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aducanumab
Therapeutic Area: Neurology Product Name: BIIB037
Highest Development Status: Phase III Product Type: Large molecule
Recipient: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2020
Details:
Clinical data from patients with Mild Cognitive Impairment due to Alzheimer’s disease and mild Alzheimer’s disease demonstrate that treatment with aducanumab resulted in the removal of amyloid beta and better clinical outcomes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: BioArctic AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
During the conference, Eisai will hold four presentations and present new information from all three on-going clinical studies with the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
